CASE STUDY 6:
ADMET Testing and Pre-Clinical Formulation Development
Wolfe Laboratories provided regular and rapid ADME testing and formulation development, which contributed to securing two years of research funding and up to $130 million in milestone payments.
Business Description
The drug discovery company focuses on designing small molecule inhibitors for oncology indications using its proprietary drug discovery platform technology.
An understanding of the metabolic liabilities and pharmacokinetic properties for this class of compounds is essential and the company relies on Wolfe Laboratories to partner with them on these essential functions and formulation development of their clinical candidates.
Technical Challenge
There was considerable opportunity for the drug discovery company to enter into licensing agreements with several large pharmaceutical companies and they needed to keep their internal engine focused on their proprietary drug discovery platform. Their drug discovery strategy required ADME characterization.
Wolfe Laboratories provided, and continues to provide, high quality, consistent and rapid ADME testing.
Wolfe Laboratories provided seamless analytical method development and formulation development for nominated development candidates.
Results
Wolfe Laboratories customized an ADME profiling program that is performed rapidly and regularly to ensure the discovery engine produces quality lead molecules at a rapid rate.
The drug discovery company entered into a licensing agreement that provided two years of R&D support, with up to $130 million in development and regulatory milestones.
